# BioLife Solutions, Inc. · Edgar & Edgarette company card

> BioLife Solutions grew revenue 28.9% in FY2025 to $96 million, operating margin -17.3% against a 7.5% median for electromedical & electrotherapeutic apparatus, equity 91.6% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 834365 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/834365) · [JSON](https://www.pops4.com/boards/company/834365.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $96M |
| Revenue growth, 1 year | 28.9% |
| Revenue growth per year | -5.2% |
| Operating margin | -17.3% (prior year -6.0%) |
| Net margin | -4.8% |
| Operating cash flow | $20M |
| Capital spending | $9M |
| Free cash flow | $11M |
| Cash | $33M |
| Long-term debt | $5M |
| Total assets | $406M |
| Total equity | $372M |
| Equity ÷ assets | 91.6% |
| Return on equity | -1.2% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: 10.32 (safe zone)
- Piotroski F: 6 of 9 (solid)
- Beneish M: -2.29 (below the −1.78 line)
- Health Harbor boat: Weathered boat · two warning signs · operating loss: a margin of -17.3% in FY2025; revenue is hard to predict: its 80% range is ±69%
- Cash Compass: In between · no clear cash pattern yet

## Edgarette's reading

Exposure: revenue $96.2M (FY2025), total debt $5.0M. Experience: revenue up 28.9% on the year, down 5.2% a year over 4 years; operating margin -17.3%, down from -6.0%. Soundness: equity 91.6% of assets, return on equity -1.2%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $46.9M and $251.0M next year (method v4.1: its own 6-year record of growth weighed at 63% against $50M–100M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $49.9M to $236.6M. A statistical range, not company guidance. Against peers (13 filers, $50M+ revenue, electromedical & electrotherapeutic apparatus): operating margin -17.3% against a 7.5% median; growth 28.9% against 8.3%.

Range logged 2026-10-01, receipt 4135851437b30443, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 3.01 Exchange listing notice or transfer: 1, latest 2026-10-06 ([filing](https://www.sec.gov/Archives/edgar/data/834365/000119312526415012/0001193125-26-415012-index.htm))
- Item 5.02 Director or officer change: 2, latest 2026-10-06 ([filing](https://www.sec.gov/Archives/edgar/data/834365/000119312526415012/0001193125-26-415012-index.htm))

## Recent filings

- 8-K · filed 2026-10-06 · 2.01 Completion of Acquisition or Disposition of Assets; 3.01 Notice of Delisting or Failure to Satisfy a Listing Rule; 3.03 Material Modifications to Rights of Security Holders; 5.01 Changes in Control of Registrant; 5.02 Departure or Election of Directors; Appointment of Officers; 5.03 Amendments to Articles or Bylaws; Change in Fiscal Year; 5.07 Submission of Matters to a Vote of Security Holders; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/834365/000119312526415012/0001193125-26-415012-index.htm)
- 8-K · filed 2026-09-09 · 8.01 Other Events · [filing](https://www.sec.gov/Archives/edgar/data/834365/000162828026061174/0001628280-26-061174-index.htm)
- 10-Q · filed 2026-08-06 · [filing](https://www.sec.gov/Archives/edgar/data/834365/000162828026054355/0001628280-26-054355-index.htm)
- 8-K · filed 2026-08-06 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/834365/000162828026054288/0001628280-26-054288-index.htm)
- 8-K · filed 2026-08-03 · 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/834365/000162828026051964/0001628280-26-051964-index.htm)
- 8-K · filed 2026-07-22 · 1.01 Entry into a Material Definitive Agreement; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/834365/000162828026049232/0001628280-26-049232-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0000834365.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=834365

## Cite

POPS4, Edgar & Edgarette: BioLife Solutions, Inc. company card, from the company's own SEC filings, accessed 2026-11-05, https://www.pops4.com/boards/company/834365. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.